Navigating HBEL Compliance: Why Your Pharma Manufacturing Needs Robust PDE and OEL Reports
5 min di lettura

Cleaning validation is a critical component of pharmaceutical quality systems, ensuring that manufacturing equipment is free of residues that could compromise product safety or quality. In recent years the industry has shifted from simple acceptance limits (e.g. “10 ppm” rules) to Health-Based Exposure Limits (HBELs), such as the Permitted Daily Exposure (PDE) and  Occupational Exposure Limit (OEL) for setting residue limits. These approaches, endorsed by regulators and industry guidelines, rely on toxicological evaluations of APIs and cleaning agents to derive safe carryover limits. In modern pharmaceutical manufacturing, maintaining safety and compliance requires strict control over cross contamination and chemical exposure for the workers in the manufacturing setup.  

Whether preventing cross-contamination in shared facilities or protecting operators on the facility floor, establishing accurate, scientifically validated PDE and OEL values is crucial for Good Manufacturing Practice (GMP) compliance. 

What Is PDE in Pharmaceuticals? 

Permitted Daily Exposure (PDE), also known as Acceptable Daily Exposure (ADE), is the substance-specific dose of an active pharmaceutical ingredient (API) that is unlikely to cause adverse health effects when an individual is exposed to that dose or less every day over a lifetime. PDE values are established through a systematic toxicological assessment of available human and nonclinical data and are used to support pharmaceutical manufacturing decisions, particularly those related to cross-contamination and cleaning validation. 

Why Is PDE Important in Pharmaceutical Manufacturing? 

PDE calculations help pharmaceutical manufacturers establish scientifically justified limits for controlling exposure to APIs and other substances. 

Key applications include: 

  • Cleaning validation: PDE values can be used to establish Maximum Allowable Carryover (MACO) and other scientifically justified limits for residual APIs and cleaning agents. 
  • Shared facility assessment: PDE values help determine whether products can be manufactured in shared facilities or whether dedicated, segregated, or contained manufacturing areas are required. 
  • Cross-contamination control: PDE assessments support risk-based strategies for preventing unacceptable levels of one product from contaminating another. 
  • Regulatory compliance: Scientifically justified PDE assessments support GMP compliance and regulatory inspection readiness. 

What Is OEL in Pharmaceutical Manufacturing? 

Occupational Exposure Limit (OEL) is the airborne concentration of an active substance to which workers may be repeatedly exposed during their working life without expected adverse health effects. While PDE primarily supports patient safety and cross-contamination control, OEL focuses on protecting workers who handle pharmaceutical substances during manufacturing, laboratory operations, sampling, dispensing, and other activities. 

Why Is OEL Important? 

OEL calculations help pharmaceutical companies understand and control the potential health risks associated with occupational exposure to APIs and other hazardous substances. Key applications include: 

  • Workplace exposure monitoring: Establishing appropriate airborne concentration limits for manufacturing and laboratory environments. 
  • Occupational exposure banding: Using OEL values to support the assignment of compounds to Occupational Exposure Bands (OEBs) and determine appropriate containment and engineering controls. 
  • Worker protection: Supporting the selection of appropriate engineering, administrative, and personal protective controls. 
  • Global compliance: Supporting occupational health and safety programs aligned with applicable regulatory and scientific standards. 

How PDE and OEL Values Are Derived ? 

Calculating robust PDE and OEL values requires a systematic toxicological evaluation by an experienced and qualified experts (DABT or ERT toxicologists). The process typically involves: 

  1. Literature Review and Hazard Identification: Systematic collection of clinical and non-clinical data, including repeat-dose toxicity, genotoxicity, reproductive toxicity, carcinogenicity and any other data such as immunogenicity, hypersensitivity including adverse clinical effects reported in clinical studies and during post marketing surveillance. 
  2. Evaluation of Critical Effects and Determining the Point of Departure (POD): Identifying critical endpoints such as No Observed Adverse Effect Level (NOAEL), No Observed Effect Level (NOEL), or Lowest Observed Adverse Effect Level (LOAEL) from nonclinical studies or lowest therapeutic/pharmacologic dose reported with significant adverse effects in humans. 
  3. Applying Safety Factors / Adjustment Factors: Adjusting for species differences, inter-individual variability, study duration, and severity of toxicity or adverse effects using scientific justification. 
  4. Specialized Routes & Approaches: Deriving route-specific PDE limits (e.g., oral, intravenous, ophthalmic, dermal, otic) and utilizing specific approaches like use of Threshold of Toxicological Concern (TTC) for genotoxic compounds as per ICH M7 guideline or deriving PDE limits for antimicrobials with specific concerns related to their effect on normal gut microflora. 

Why Are PDE and OEL Reports Important? 

A scientifically robust PDE or OEL report provides a documented and defensible rationale for the exposure limit assigned to a substance. 

For pharmaceutical manufacturers, this documentation can support: 

  • Cleaning validation and MACO calculations 
  • Cross-contamination risk assessments 
  • Shared versus dedicated facility decisions 
  • Containment strategy development 
  • Occupational exposure monitoring 
  • Occupational exposure banding 
  • GMP inspection and audit readiness 
  • Pharmaceutical facility commissioning 

The quality of the final PDE or OEL value depends not only on the mathematical calculation but also on the quality of the underlying toxicological evaluation, data interpretation and scientific justification. 

Why Partner with Leading Service Provider like Freyr? 

Outsourcing PDE and OEL calculations to highly experienced and reputed service provider like Freyr offers several critical operational and regulatory benefits: 

  • Audit Readiness: Defensible, fully referenced monographs that withstand scrutiny during GMP inspections and regulatory audits. Freyr provides unlimited support for any regulatory or audit queries without any additional cost. 
  • Expertise in Complex Routes: Tailored calculations for non-standard routes of administration or novel drug delivery systems. 
  • Comprehensive Coverage: Dual reports assessing both patient risk (PDE) and worker safety (OEL) in a single workflow (a single combined PDE and OEL report). 
  • Efficiency: On priority delivery of reports on demand by streamlined evaluations that prevent delays in cleaning validation protocols or facility commissioning.  

Setting accurate PDE and OEL limits is not just a regulatory checkmark- it is a critical safety foundation for pharmaceutical operations. By combining clinical insight with rigorous toxicological risk assessment, manufacturers can ensure patient safety, protect their workforce, and maintain seamless compliance across global regulatory requirements. 

Looking to streamline your HBEL compliance?  

With over a decade of dedicated experience and a global team of toxicologists, Freyr delivers scientifically robust, audit-ready PDE and OEL assessments tailored to your specific requirements. From cleaning validation and cross-contamination control to occupational safety, our assessments provide the scientific rationale you need to make confident, compliant decisions. 

Frequently Asked Questions About PDE and OEL

A PDE report is a scientifically documented toxicological assessment that establishes the Permitted Daily Exposure value for a substance. It typically includes a review of available safety data, identification of critical effects and point of departure, application of appropriate adjustment factors, and the scientific rationale for the final PDE value.

An OEL report documents the toxicological assessment used to establish an Occupational Exposure Limit for a substance. The report provides the scientific rationale for the airborne exposure limit intended to protect workers from adverse health effects.

No. PDE and OEL are not the same. PDE is primarily used to control patient exposure and pharmaceutical cross-contamination, while OEL is primarily used to protect workers from occupational exposure.

PDE provides a health-based scientific basis for determining acceptable carryover of an API from one product or manufacturing campaign to another. PDE values can therefore be used in the development of scientifically justified cleaning validation and MACO limits.

PDE assessments should be performed and scientifically reviewed by appropriately qualified toxicologists with expertise in pharmaceutical toxicology, toxicological risk assessment and interpretation of human and nonclinical safety data.

PDE assessments are commonly required when establishing health-based limits for pharmaceutical substances, particularly for cleaning validation, cross-contamination control and shared facility assessments. The specific requirement depends on the substance, manufacturing process and applicable regulatory expectations.

Health-Based Exposure Limit (HBEL) is an exposure limit derived from toxicological and pharmacological data to protect individuals from unacceptable health risks. PDE and OEL are important examples of health-based exposure limits used in pharmaceutical manufacturing.

Iscriviti al blog di Freyr